Literature DB >> 9354667

PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes.

A Himmelmann1, A Riva, G L Wilson, B P Lucas, C Thevenin, J H Kehrl.   

Abstract

CD20 is a B-lineage-specific gene expressed at the pre-B-cell stage of B-cell development that disappears on differentiation to plasma cells. As such, it serves as an excellent paradigm for the study of lineage and developmental stage-specific gene expression. Using in vivo footprinting we identified two sites in the promoter at -45 and -160 that were occupied only in CD20+ B cells. The -45 site is an E box that binds basic helix-loop-helix-zipper proteins whereas the -160 site is a composite PU.1 and Pip binding site. Transfection studies with reporter constructs and various expression vectors verified the importance of these sites. The composite PU.1 and Pip site likely accounts for both lineage and stage-specific expression of CD20 whereas the CD20 E box binding proteins enhance overall promoter activity and may link the promoter to a distant enhancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354667

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

4.  Dissection of CD20 regulation in lymphoma using RNAi.

Authors:  M Słabicki; K S Lee; A Jethwa; L Sellner; F Sacco; T Walther; J Hüllein; S Dietrich; B Wu; D B Lipka; C C Oakes; S Mamidi; B Pyrzyńska; M Winiarska; M Oleś; M Seifert; C Plass; M Kirschfink; M Boettcher; J Gołąb; W Huber; S Fröhling; T Zenz
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

5.  IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner.

Authors:  Seung-Hee Jo; Ruibao Ren
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

6.  Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression.

Authors:  Thierry Roger; Isabelle Miconnet; Anne-Laure Schiesser; Hirofumi Kai; Kensuke Miyake; Thierry Calandra
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

7.  Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.

Authors:  Ping-Chiao Tsai; Francisco J Hernandez-Ilizaliturri; Naveen Bangia; Scott H Olejniczak; Myron S Czuczman
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

8.  PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells.

Authors:  Kevin S Choe; Olga Ujhelly; Sandeep N Wontakal; Arthur I Skoultchi
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

Review 9.  IRF4: Immunity. Malignancy! Therapy?

Authors:  Arthur L Shaffer; N C Tolga Emre; Paul B Romesser; Louis M Staudt
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

10.  Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Takaaki Hato; Jun Yamanouchi; Tatsushiro Tamura; Norimasa Hojo; Yasunari Niiya; Masashi Kohno; Shiro Bando; Yoshihiro Yakushijin; Kiyonori Takada; Ikuya Sakai; Masaki Yasukawa; Shigeru Fujita
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.